ENDPOINTS – Page 10 – Endpoints News

about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher

Last year

Pharming ends deal with Orchard; Seres considers cost-cutting

Last year

Lykos’ MDMA therapy to go before FDA committee; GSK expands work with BioVersys

Last year

Gates, Novo Nordisk, Wellcome foundations put $300M in global health; BioNTech stops prostate cancer study

Last year

Royalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering

Last year

Context Therapeutics' $100M placement; Blueprint raises guidance for rare disease drug

Last year

Editas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE program

Last year

Daré's royalty deal; Qlaris Bio raises $24M

Last year

Cerevance's $47M raise; Parexel's AI pact

Last year

Centessa's public offering; Vivoryon ends Ph2 Alzheimer’s trial

Last year

Shimadzu Corporation establishes three R&D centers in the US in anticipation of business expansion for pharmaceutical ...

Last year

Nikkei Biotechnology

GNI Group to form $100M fund with Chinese state-owned enterprises

Last year

Nikkei Biotechnology

Brise raises $20M; Taro shareholder criticizes Sun Pharma deal

Last year

Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trial

Last year

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Last year

Biohaven’s $230M offering; Plus, three new PIPEs

Last year

Intra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered programs

Last year

Takeda’s new deal with Kumquat; IL-2 biotech raises $55M

Last year

Mustang Bio to lay off workers; MaaT's new data for microbiome therapy

Last year

Japanese pharmaceutical regulations under review to resolve drug shortages and ensure stable supply

Last year

Nikkei Biotechnology

Nurix's $175M offering; Invivyd CEO is out

Last year

Century Therapeutics buys Clade; Eliem announces $120M PIPE and a deal

Last year

Skye Bioscience uplists; OncoX's licensing deal with ABVC BioPharma

Last year

Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data

Last year

First page Previous page 7 8 91011 12 13 Next page Last page